COMP <GO>
SCTX vs ABBV // FORWARD P/E MULTIPLE
Scribe Therapeutics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: SCTX 0
— ABBV 3
■ METRIC PARITY
LAST: $17.44 (-0.57%) • MKT CAP: $330.2M
forward-pe
—
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SCTX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SCTX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | 29.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 3.47% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | 24.60% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 6.90% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 8.60% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.33 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 7/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.8 | 65.1 | -28.34 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $330.2M | $513.86B | -$513.53B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SCTX REV | ABBV REV | SCTX GROSS % | ABBV GROSS % | SCTX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $61.16B | — | 70.2% | — | $17.82B |
| FY 2024 | — | $56.33B | — | 70.0% | — | $17.83B |
| FY 2023 | — | $54.32B | — | — | — | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SCTX // BETA —
ABBV // BETA 1.15